Database Query Results : , , PD-L1

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
1023- AL,    Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway
- in-vitro, NA, NA - Analysis, NA, NA
PD-L1↓,
1024- Api,  CUR,    Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
- vitro+vivo, Melanoma, A375 - in-vitro, Melanoma, A2058 - in-vitro, Melanoma, RPMI-7951
TumCG↓, Apoptosis↑, PD-L1↓, STAT1↓, tumCV↓, T-Cell↑,
1026- ART/DHA,    PD-L1_therapy_in_T-cell_lymphoma">Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
Ferroptosis↑, ROS↑, ERK↓, PD-L1↓,
1027- AS,    Astragalus polysaccharide (APS) attenuated PD-L1-mediated immunosuppression via the miR-133a-3p/MSN axis in HCC
- vitro+vivo, HCC, SMMC-7721 cell
PD-L1↓, miR-133a-3p↝,
1028- ASA,    Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
- vitro+vivo, Ovarian, NA
TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP↑, p‑eIF2α↑, ICD↑, eff↑,
1029- Ba,  BA,    Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
- vitro+vivo, HCC, NA
PD-L1↓, T-Cell↑, STAT3↓,
1032- BA,    Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer
- in-vivo, GC, AGS
GutMicro↑, PD-L1↓, IL10↓, TumCG↓,
2290- Ba,    Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer
- Review, GI, NA
p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB/CCNB1↓, cycD1/CCND1↓, cycA1/CCNA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,
2292- Ba,  BA,    Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives
- Review, Var, NA
AntiCan↑, *toxicity↓, BioAv↝, BioAv↓, *ROS↓, *TLR2↓, *NF-kB↓, *NRF2↑, *antiOx↑, *Inflam↓, HDAC1↓, HDAC8↓, Wnt↓, β-catenin/ZEB1↓, PD-L1↓, Sepsis↓, NF-kB↓, LOX1↓, COX2↓, VEGF↑, PI3K↓, Akt↓, mTOR↓, MMP2↓, MMP9↓, SIRT1↑, AMPK↑,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
1030- BBR,    Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5
- in-vitro, Lung, H460
PD-L1↓, TumCG↓, Ki-67↓, cl‑Casp3↑,
1031- BCA,    Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer
- vitro+vivo, CRC, HCT116 - vitro+vivo, CRC, SW-620
PD-L1↓, TumCG↓, Zeb1↓, E-cadherin↑, N-cadherin↓, EMT↓,
741- Bor,    Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
MOB1↓, PD-L1↑, p‑YAP/TEAD↝, IFN-γ↓, sFasL↑, Perforin↓, GranA↓, GranB↓, GNLY↓, PD-1↑,
2017- CAP,    Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease
- Review, Var, NA
RenoP↑, AntiTum↑, AMPK↑, mTOR↑, PD-1↓, PD-L1↓,
1244- CGA,  immuno,    Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody
- in-vivo, NA, NA
PD-L1↓, T-Cell↑, eff↑,
1033- CHr,    Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression
- vitro+vivo, HCC, NA
TumCG↓, CD4+↑, CD8+↑, PD-L1↓,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
1035- DHA,    Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation
- vitro+vivo, NA, NA
PD-L1↓, FASN↓,
4916- DSF,  Cu,    The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
- Review, Var, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Imm↑, ROS↑, NF-kB↓, chemoP↑, JNK↑, FOXO↑, Myc↑, TumCCA↑, Apoptosis↑, RadioS↑, PD-L1↑, eff↑, CSCs↓, Dose↝, Half-Life↑,
1037- EA,    Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction
- in-vivo, CRC, NA
AntiTum↑, PD-L1↓,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1022- EDM,    Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis
- in-vivo, Lung, H1975 - in-vitro, Lung, H1650
TumCG↓, Apoptosis↑, TumCCA↑, PD-L1↓, MUC1-C↓, TumVol↓,
1036- EGCG,    Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
- in-vitro, Lung, A549 - in-vitro, Lung, LU99
PD-L1↓, EGF↓, Akt↓,
1039- F,    Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network
- in-vitro, NA, NA
TumCP↓, Apoptosis↑, PD-L1↓,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
1021- HNK,    Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
- in-vivo, Lung, NA
PD-L1↓, T-Cell↑, CD4+↑, CD8+↑, TumCG↓,
1004- HNK,  RAPA,    PD-L1_expression_and_enhances_antitumor_effects_of_mTOR_inhibitors_in_renal_cancer_cells">Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells
- in-vitro, RCC, NA
Apoptosis↑, TumCCA↑, ROS↑, PD-L1↓, IFN-γ↓,
1040- LE,    Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration
- in-vivo, Lung, H1975
TumCCA↑, CDK4↓, cycD1/CCND1↓, PD-L1↑, TumVol↓,
1025- LT,  Api,    Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
- in-vivo, Lung, NA
TumCG↓, Apoptosis↑, PD-L1↓, p‑STAT3↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, NA, NA
eff↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
1044- Myr,    Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
- in-vitro, Lung, NA
PD-L1↓, IDO1↓,
1045- OLST,    Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
- in-vitro, AML, Jurkat
FASN↓, TumCG↓, PD-L1↓,
1813- Oxy,    Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment
- Review, Var, NA
ChemoSen↑, RadioS↑, PD-L1↓, Hif1a↓, ROS↑,
1047- RES,    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells
- in-vitro, Lung, H1299 - in-vitro, Lung, A549 - in-vitro, Lung, H460
PD-L1↑, Snail↑, E-cadherin↓, N-cadherin↑, Fibronectin↑, Vim↑, Axin2↓,
1048- RosA,  Ger,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, NA, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
337- SNP,  immuno,    Silver nanoparticle induced immunogenic cell death can improve immunotherapy
- Review, NA, NA
PD-L1↓,
1052- TQ,    Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
NRF2↑, PD-L1↓, Apoptosis↑,
3399- TQ,    Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - NA, BC, MDA-MB-468
ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
4538- TQ,    PD-L1_in_MDA-MB-231_Triple-Negative_Breast_Cancer_Cells">Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
antiOx↑, H2O2↓, Catalase↑, SOD↑, GSH↑, PRNP↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, chemoPv↑, ROS↓,
3141- VitC,    High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
- in-vitro, CRC, HCT116
Glycolysis↓, eff↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 49

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↑, 2,   Copper↑, 1,   Ferroptosis↑, 1,   GCLM↑, 2,   GPx1⇅, 1,   GPx4↓, 2,   GSH↓, 1,   GSH↑, 2,   GSSG↑, 1,   H2O2↓, 2,   HO-1↓, 2,   HO-2↓, 1,   ICD↑, 1,   lipid-P↑, 1,   NQO1↑, 2,   NRF2↓, 2,   NRF2↑, 3,   OXPHOS↑, 1,   ROS↓, 4,   ROS↑, 12,   SOD↑, 2,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   mt-ATP↓, 1,   EGF↓, 1,   MMP↓, 4,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   i-citrate↑, 1,   cMyc↓, 2,   ECAR↝, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 1,   IDO1↓, 1,   lactateProd↓, 2,   LDHA↓, 2,   PDK1?, 2,   PDK1↓, 1,   PDK3↑, 1,   PKM2↓, 2,   p‑PKM2↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   Akt↑, 1,   p‑Akt↓, 4,   Apoptosis↑, 9,   BAD↑, 1,   Bak↑, 1,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 3,   Casp↑, 3,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp9↑, 2,   Cyt‑c↑, 3,   Diablo↑, 1,   DR5↑, 1,   Ferroptosis↑, 1,   GranA↓, 1,   GranB↓, 1,   iNOS↓, 1,   JNK↑, 1,   Mcl-1↓, 1,   MDM2↓, 1,   Myc↓, 1,   Myc↑, 1,   NOXA↑, 1,   p27↑, 2,   Perforin↓, 1,   PUMA↑, 1,   sFasL↑, 1,   survivin↓, 3,   Telomerase↓, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,   p‑YAP/TEAD↝, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 2,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes ⓘ

LC3A↑, 1,   p62↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   P53↑, 4,   cl‑PARP↑, 3,   PCNA↓, 1,   SIRT6↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 3,   CDK4↓, 4,   Cyc↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   E2Fs↓, 1,   P21↑, 4,   p‑RB1↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

Axin2↓, 1,   CD44↓, 1,   CDK8↓, 1,   CSCs↓, 1,   EMT↓, 6,   ERK↓, 2,   p‑ERK↓, 1,   FOXO↑, 1,   GSK‐3β↓, 1,   H3K27ac∅, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC10↓, 1,   HDAC8↓, 1,   IGFBP3↑, 1,   miR-34a↑, 1,   mTOR↓, 2,   mTOR↑, 1,   p‑mTOR↓, 2,   NOTCH↓, 2,   NOTCH1↑, 1,   PI3K↓, 4,   p‑PI3K↓, 1,   PTEN↑, 2,   Shh↓, 1,   STAT1↓, 1,   STAT3↓, 5,   p‑STAT3↓, 3,   TAZ↓, 1,   TOP1↓, 1,   TumCG↓, 13,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 2,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   FAK↓, 1,   p‑FAK↓, 2,   Fibronectin↑, 1,   Galectin-9↓, 1,   Ki-67↓, 3,   Ki-67↑, 1,   L-sel↑, 1,   miR-133a-3p↝, 1,   miR-203↑, 1,   MMP2↓, 6,   MMP9↓, 5,   MMP9↑, 1,   MOB1↓, 1,   MUC1-C↓, 1,   N-cadherin↓, 2,   N-cadherin↑, 1,   PDGF↓, 1,   PKCδ↓, 1,   PRNP↑, 1,   Rho↓, 1,   ROCK1↓, 3,   Slug↓, 1,   SMAD3↓, 1,   Snail↓, 3,   Snail↑, 1,   TGF-β↓, 2,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 7,   TumMeta↓, 2,   Twist↓, 2,   uPA↓, 2,   Vim↓, 3,   Vim↑, 1,   Zeb1↓, 3,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   EGFR↓, 2,   p‑EGFR↓, 2,   Endoglin↑, 1,   HIF-1↓, 1,   Hif1a↓, 5,   LOX1↓, 1,   VEGF↓, 6,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 2,   NHE1↓, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 1,   CD4+↓, 1,   CD4+↑, 3,   COX1↓, 1,   COX2↓, 6,   FoxP3+↓, 1,   GNLY↓, 1,   IFN-γ↓, 3,   IFN-γ↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL2↑, 1,   IL6↓, 3,   Imm↑, 1,   Inflam↓, 2,   JAK↓, 1,   JAK2↓, 1,   NF-kB↓, 8,   PD-1↓, 3,   PD-1↑, 1,   PD-L1↓, 43,   PD-L1↑, 6,   PD-L2↓, 1,   PGE2↓, 1,   PSA↓, 1,   T-Cell↑, 5,   TILs↑, 1,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

TIM-3↓, 1,   TIM-3↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 6,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 1,   Dose↝, 4,   Dose∅, 1,   eff↓, 3,   eff↑, 12,   eff↝, 1,   Half-Life↓, 2,   Half-Life↑, 1,   Half-Life↝, 1,   RadioS↑, 4,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 2,   EGFR↓, 2,   p‑EGFR↓, 2,   GutMicro↑, 1,   IL6↓, 3,   Ki-67↓, 3,   Ki-67↑, 1,   Myc↓, 1,   Myc↑, 1,   PD-L1↓, 43,   PD-L1↑, 6,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 2,   cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   RenoP↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 3,   TumW↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 4,   Sepsis↓, 1,  
Total Targets: 274

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 2,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Migration ⓘ

TIMP1↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   Inflam↓, 3,   NF-kB↓, 1,   TLR2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 2,   toxicity∅, 2,  
Total Targets: 18

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
5 immunotherapy
4 Baicalein
4 Thymoquinone
3 Silymarin (Milk Thistle) silibinin
2 Apigenin (mainly Parsley)
2 Curcumin
2 Baicalin
2 Chrysin
2 Ellagic acid
2 Honokiol
1 Allicin (mainly Garlic)
1 Artemisinin
1 Astragalus
1 Aspirin -acetylsalicylic acid
1 Ashwagandha(Withaferin A)
1 Butyrate
1 Berberine
1 Biochanin A
1 Boron
1 Capsaicin
1 Chlorogenic acid
1 Propolis -bee glue
1 Docosahexaenoic Acid
1 Disulfiram
1 Copper and Cu NanoParticlex
1 Evodiamine
1 EGCG (Epigallocatechin Gallate)
1 Fucoidan
1 Gallic acid
1 Rapamycin
1 Licorice
1 Luteolin
1 Melatonin
1 Metformin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Myricetin
1 Orlistat
1 Oxygen, Hyperbaric
1 Resveratrol
1 Rosmarinic acid
1 Germacranolide
1 Shikonin
1 Silver-NanoParticles
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:243  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page